Biologics in Plaque Psoriasis

An assessment of the current reimbursement of biologics used to treat adults with moderate-to-severe plaque psoriasis (PsO) is needed given the significant expenditures on biologics and the changing dynamics because of loss of exclusivity and new-generation biologic entrants. This Environmental Scan assessed the regulatory, exclusivity, CADTH review, and reimbursement status of biologics for PsO relevant to public drug plans.

There is significant utilization of old-generation originators in new claimants despite the availability of new-generation biologics which have direct comparative evidence to support superiority. Marketing of old-generation biosimilars has been delayed for more than 3 years, and several old-generation biologics have no biosimilar versions available despite loss of exclusivity.

Old-generation originators largely predate the pCPA process, thus their reimbursement is less likely to be associated with a listing agreement. Overall, formulary management strategies could be employed for payers to optimize patient outcomes.